Get the Stockscreener App
423.92
0.81%
-3.46
After Hours:
421.60
-2.32
-0.55%
Vertex Pharmaceuticals Inc stock is traded at $423.92, with a volume of 796.43K.
It is down -0.81% in the last 24 hours and down -5.22% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$427.38
Open:
$425.02
24h Volume:
796.43K
Relative Volume:
0.59
Market Cap:
$107.83B
Revenue:
$12.07B
Net Income/Loss:
$3.95B
P/E Ratio:
27.64
EPS:
15.3349
Net Cash Flow:
$3.19B
1W Performance:
-1.48%
1M Performance:
-5.22%
6M Performance:
-0.39%
1Y Performance:
-15.02%
1-Day Range:
$421.54
$427.38
1-Week Range:
$419.71
$434.07
52-Week Range:
$362.50
$509.00
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
PFA Pension Forsikringsaktieselskab Takes Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Oppenheimer Asset Management Inc. - MarketBeat
How Investors Are Reacting To Vertex (VRTX) FDA ALYFTREK Expansion and Evolving Pipeline Story - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect - The Globe and Mail
Vertex (VRTX) Named Top Biotech Pick for 2026 by BofA - Yahoo Finance
3,167 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Sandro Wealth Management LLC - MarketBeat
VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying? - AOL.com
Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying? - The Motley Fool
Rule 144 notice: Joy Liu reports VRTX share sales (VRTX) - Stock Titan
How Will Vertex Pharmaceuticals Stock React To Its Upcoming Earnings? - Trefis
Danske Bank A S Decreases Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
VRTX Maintained by Canaccord Genuity -- Price Target Lowered to $437 - GuruFocus
Vertex Pharmaceuticals (VRTX) Announces Board Changes Ahead of 2 - GuruFocus
[SCHEDULE 13G] VERTEX PHARMACEUTICALS INC / MA Passive Investment Disclosure (>5%) - Stock Titan
Vertex Pharmaceuticals Incorporated $VRTX Stake Reduced by Jennison Associates LLC - MarketBeat
Vertex Pharmaceuticals Earnings Notes - Trefis
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Vertex (NASDAQ: VRTX) trims board to ten as Suketu Upadhyay steps aside - Stock Titan
Wealthfront Advisers LLC Boosts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) exceeds market returns: Some facts to consider - MSN
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Stock with Promising Technical Setup - ChartMill
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect - Yahoo Finance
Vertex Pharma stock (US92532F1003): Is cystic fibrosis dominance still enough for long-term upside? - AD HOC NEWS
A Look At Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness - Yahoo Finance
Mitsubishi UFJ Trust & Banking Corp Has $73.54 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals heading to $600? - MSN
Vertex Pharmaceuticals (NASDAQ:VRTX) Rating Increased to Strong-Buy at Truist Financial - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Holdings Raised by Exencial Wealth Advisors LLC - MarketBeat
Concurrent Investment Advisors LLC Raises Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Stock Position Lowered by Pictet Asset Management Holding SA - MarketBeat
State of Michigan Retirement System Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Sanctuary Advisors LLC Boosts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma wins FDA label expansion for cystic fibrosis therapies - MSN
Vertex Pharmaceuticals Incorporated (VRTX) is attracting investor attention: Here is what you should know - MSN
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Vanguard Group Inc. - MarketBeat
Vertex Pharma in pact with Halozyme for Hypercon drug delivery tech - MSN
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vertex Pharmaceuticals Incorporated (VRTX) PT Nudged Higher as RBC Updates Biotech Sector Outlook - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by M&T Bank Corp - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by China Universal Asset Management Co. Ltd. - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Arizona State Retirement System - MarketBeat
Teacher Retirement System of Texas Decreases Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Evergreen Capital Management LLC Buys 2,304 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
B. Metzler seel. Sohn & Co. AG Buys 199,847 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc. (VRTX)Bullish Jim Cramer Endorsement Highlights Divergent Sentiment Amid Mixed Pipeline UpdatesAsset Sale - Xã Thanh Hà
Best Biotech Stocks To Watch TodayApril 22nd - MarketBeat
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $577 - Moomoo
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vertex Pharmaceuticals Inc Stock (VRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Liu Joy | EVP and Chief Legal Officer |
Apr 01 '26 |
Sale |
449.17 |
978 |
439,288 |
21,833 |
0.80%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):